source
- Boulevard Bio raises $65M to expand immunology pipeline, eyes Vera's IgAN candidateBoulevard Bio announced it has secured $65 million in financing to broaden its immunology portfolio. The new capital will support the development of two immune‑resetting drugs the company discovere…
- Aardvark Therapeutics abandons phase 3 trials after workforce cuts and FDA holdAardvark Therapeutics announced it is walking away from its recently terminated phase 3 trials, stating there are no plans to resume them as originally designed. The decision follows a reduction i…